- Home
- KTTA vs ENSC Comparison
KTTA vs ENSC Comparison
Compare KTTA & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- ENSC
- Stock Information
- Founded
- KTTA 2020
- ENSC 2003
- Country
- KTTA United States
- ENSC United States
- Employees
- KTTA N/A
- ENSC N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- ENSC Health Care
- Exchange
- KTTA Nasdaq
- ENSC Nasdaq
- Market Cap
- KTTA 5.5M
- ENSC 6.4M
- IPO Year
- KTTA 2021
- ENSC N/A
- Fundamental
- Price
- KTTA $0.81
- ENSC $2.39
- Analyst Decision
- KTTA
- ENSC
- Analyst Count
- KTTA 0
- ENSC 0
- Target Price
- KTTA N/A
- ENSC N/A
- AVG Volume (30 Days)
- KTTA 93.8K
- ENSC 108.5K
- Earning Date
- KTTA 11-12-2025
- ENSC 11-11-2025
- Dividend Yield
- KTTA N/A
- ENSC N/A
- EPS Growth
- KTTA N/A
- ENSC N/A
- EPS
- KTTA N/A
- ENSC N/A
- Revenue
- KTTA N/A
- ENSC $7,413,722.00
- Revenue This Year
- KTTA N/A
- ENSC N/A
- Revenue Next Year
- KTTA N/A
- ENSC $1,354.55
- P/E Ratio
- KTTA N/A
- ENSC N/A
- Revenue Growth
- KTTA N/A
- ENSC 415.58
- 52 Week Low
- KTTA $0.65
- ENSC $1.62
- 52 Week High
- KTTA $5.45
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- KTTA 61.44
- ENSC 58.50
- Support Level
- KTTA $0.70
- ENSC $2.35
- Resistance Level
- KTTA $0.84
- ENSC $2.64
- Average True Range (ATR)
- KTTA 0.03
- ENSC 0.16
- MACD
- KTTA 0.01
- ENSC 0.02
- Stochastic Oscillator
- KTTA 81.57
- ENSC 51.79
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.